Pingkuan Zhang, M.D.
Senior Vice President, Oncology Development
Pingkuan Zhang, M.D., is senior vice president of oncology development at BlossomHill Therapeutics. She has more than 20 years of experience in the pharmaceutical industry. Most recently, she was executive medical director of Takeda Oncology’s lung cancer portfolio and T-cell engagers. Prior to Takeda, Dr. Zhang was the medical director of global clinical development at Novartis Oncology and medical director of oncology, global drug development, where she led the melanoma and lung cancer programs, respectively. She has broad experience in the global pharmaceutical industry through her tenure in GSK, AstraZeneca and Sanofi in China before taking global R&D roles.
In her career, Dr. Zhang has delivered multiple successful development programs, including brigatinib (Alunbrig®) in ALK fusion NSCLC, dabrafenib (Tafinlar®) and trametinib (Mekinist®) in BRAF V600E mutation NSCLC globally, in addition to line extension of gefitinib (Iressa®) in lung cancer and oxaliplatin (Eloxatin®) in hepatocellular carcinoma in China. Additionally, she has extensive experience building and managing teams, having established the oncology clinical science team at GSK China R&D and the lung cancer clinical science team at Takeda U.S.
Dr. Zhang received her M.D. and M.S. from Shanghai Medical College, Fudan University. She practiced medicine at Shanghai Chest Hospital and conducted clinical studies in academic institutes before joining the life sciences industry.